Institutional Career Development Core

机构职业发展核心

• 批准号: 10668274
• 负责人: Charles C Miller
• 金额: $ 116.64万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-24 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10668274
• 关键词: Achievement; Age; Bayesian Method; Beds; Cancer Center; Child; Clinical; Clinical Investigator; Clinical Research; Clinical Sciences; Clinical Skills; Collaborations; Comparative Effectiveness Research; Deimplementation; Dentistry; Development Plans; Disadvantaged; Discipline of Nursing; Disparity population; Educational Curriculum; Educational workshop; Effectiveness; Emergency treatment; Environment; Ethics; Faculty; Funding; Grant; Health; Health Care Research; Health Professional; Health Sciences; Health system; Healthcare; Healthcare Systems; Industry; Infrastructure; Institution; Institutional Review Boards; Interdisciplinary Study; Joints; Journals; Learning; Medical center; Medicine; Mentors; Mentorship; Methodology; Methods; Outcome; Participant; Patients; Performance; Population Heterogeneity; Pregnant Women; Productivity; Public Health Schools; Publishing; Research; Research Design; Research Personnel; Research Training; Safety; Science; Secure; Services; Talents; Texas; Training; Translational Research; Universities; biomedical informatics; care delivery; career development; clinical care; college; community engagement; cost; economic evaluation; graduate school; health care consultation; high risk; implementation research; improved; innovation; investigator training; medical schools; meetings; multidisciplinary; novel; patient population; population health; programs; success; translational scientist

Few single institutions can meet the differing training needs of all types of clinical and translational (C&T) (T1- T4) investigators. The University of Texas Health Science Center at Houston (UTHSC-H) and the UT MD Anderson Cancer Center (UT MDACC) have a unique partnership with overlapping strengths and close proximity that allow us to meet these needs. Most T1-2 training is provided at UT MDACC and our joint Graduate School of Biomedical Sciences. T2-T4 research is based at UTHSC-H McGovern Medical School in collaboration with our Schools of Public Health, Biomedical informatics, Nursing, and Dentistry. We are applying for a CTSA to fund 6 KL2 Scholars per yr. To maximize the number and achievements of the C&T investigators trained by our hub, we will leverage CTSA funding to also support 6 Institutional Scholars per yr and enhance our program developing skilled C&T investigators throughout the immense Texas Medical Center (TMC) (9200 beds and 10 million encounters per yr) serving an extremely diverse patient population. Our Program includes: 1) the Clinical and Translational Research Curriculum (510 participants in past 5 yrs; 11 basic courses/workshops required for Scholars); 2) MS Courses & Degree in Clinical Research (65 TMC faculty & fellows in the past 5 yrs; optional for Scholars & tailored to an career development plan); and 3) the central focus of our Core: an Intensive Mentorship Program, (28 KL2 or Institutional Scholars & 27 other talented C&T investigators in past 5 yrs) that has been highly successful in helping mentees from our institutions, Baylor College of Medicine, and elsewhere to secure major grants, publish in high impact journals (NEJM, JAMA, and others), and become institutional and national academic leaders. Special strengths include our Scholars’ research success involving multidisciplinary teams and other CTSA centers; improving the delivery, safety, and effectiveness of healthcare for pregnant women, children, and disadvantaged patients of any age; advancing the methods of C&T research using n-of-1 trials, Bayesian methods, and economic analyses; and showing reduced health system costs to secure adequate reimbursements to sustain and expand improved approaches to care delivery. Innovations in the next cycle will augment these strengths, enhance T1 research training, team science research, and interaction with industry, and promote learning health care (LHC) research through a novel LHC consultation service, a continuous community engagement program, and a special IRB panel to facilitate and advance the science and ethics of comparative effectiveness research, trials of emergency therapies, and implementation/de-implementation research. These and other Core features will promote the career development of Scholars within a LHC system to most rapidly advance clinical care and the health of diverse populations. With these innovations and our track record, infrastructure, and institutional support, CTSA funding will predictably produce a large return by developing innovative, collaborative, rigorous, and productive C&T investigators.

很少有单一机构能够满足所有类型的临床和转换(C&T)的不同培训需求(T1- T4)调查人员。德克萨斯大学休斯顿健康科学中心(UTHSC-H)和UT MD 安德森癌症中心(UT MDACC)拥有独特的合作伙伴关系，优势重叠，关系密切 使我们能够满足这些需求的接近。大部分T1-2培训在UT MDACC和我们的联合机构提供 生物医学研究生院。T2-T4研究的基础是UTHSC-H麦戈文医学院 与我们的公共卫生、生物医学信息学、护理和牙科学院合作。我们是 申请CTSA每年资助6名KL2奖学金获得者。最大限度地提高科技人员的数量和成果 由我们的中心培训的研究人员，我们将利用CTSA资金每年还支持6名机构学者 并加强我们在整个庞大的德克萨斯医疗中心培养熟练的C&T调查人员的计划 (TMC)(每年9200张床位和1000万人次就诊)，为极其多样化的患者群体提供服务。我们的 计划包括：1)临床和转化研究课程(过去5年有510人参加；11人参加 学者必修的基础课程/讲习班)；2)临床研究硕士课程和学位(65 TMC 过去5年的教师和研究员；学者可选，并为职业发展计划量身定做)；以及3) 我们核心的中心焦点：密集的导师计划，(28名KL2或机构学者和27名其他 过去5年中才华横溢的C&T调查人员)，在帮助我们的学员方面非常成功 机构，贝勒医学院和其他地方，为获得主要赠款，在影响较大的期刊上发表文章 (NEJM、JAMA和其他)，并成为机构和国家学术领袖。 特别优势包括我们的学者们在涉及多学科团队和其他CTSA的研究方面取得的成功 中心；改善孕妇、儿童和儿童保健的交付、安全和有效性 任何年龄段的弱势患者；使用n-of-1试验推进C&T研究方法，贝叶斯 方法和经济分析；并显示降低了卫生系统成本，以确保适当 用于维持和扩大经改进的护理提供方法的补偿。下一个周期的创新将 增强这些优势，加强T1研究培训、团队科学研究以及与行业的互动， 并通过新的LHC咨询服务促进学习卫生保健(LHC)研究，该服务是一项持续的 社区参与计划，以及一个特别的IRB小组，以促进和促进 比较有效性研究、紧急治疗试验和实施/取消实施 研究。这些和其他核心特征将促进大型强子对撞机内学者的职业发展 最快推进临床护理和不同人群健康的系统。凭借这些创新和 我们的记录、基础设施和机构支持，CTSA的资金将可以预见地产生巨大的回报 通过培养创新、协作、严谨和富有成效的C&T调查人员。

项目成果

Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.

• DOI: 10.1016/s1470-2045(22)00638-6
• 发表时间: 2022-12
• 期刊: LANCET ONCOLOGY
• 影响因子: 51.1
• 作者: Guadagnolo, B. Ashleigh;Bassett, Roland L.;Mitra, Devarati;Farooqi, Ahsan;Hempel, Caroline;Dorber, Courtney;Willis, Tiara;Wang, Wei-Lien;Ratan, Ravin;Somaiah, Neeta;Benjamin, Robert S.;Torres, Keila E.;Hunt, Kelly K.;Scally, Christopher P.;Keung, Emily Z.;Satcher, Robert L.;Bird, Justin E.;Lin, Patrick P.;Moon, Bryan S.;Lewis, Valerae O.;Roland, Christina L.;Bishop, Andrew J.
• 通讯作者: Bishop, Andrew J.

Effectiveness of Standard Local Anesthetic Bupivacaine and Liposomal Bupivacaine for Postoperative Pain Control in Patients Undergoing Truncal Incisions: A Randomized Clinical Trial.

• DOI: 10.1001/jamanetworkopen.2021.0753
• 发表时间: 2021-03-01
• 期刊: JAMA network open
• 影响因子: 13.8
• 作者: Sandhu HK;Miller CC 3rd;Tanaka A;Estrera AL;Charlton-Ouw KM
• 通讯作者: Charlton-Ouw KM

The Role of Biologic Mesh and Fundoplication in the Surgical Management of Hiatal Hernias: A Multicenter Evaluation.

生物补片和胃底折叠术在食管裂孔疝手术治疗中的作用：多中心评估。

• DOI: 10.1159/000533186
• 发表时间: 2023
• 期刊: Digestive surgery
• 影响因子: 2.7
• 作者: Mohr,Cassandra;Ciomperlik,Hailie;Dhanani,Naila;Olavarria,OscarA;Hannon,Craig;Hope,William;Roth,Scott;Liang,MikeK;Holihan,JulieL
• 通讯作者: Holihan,JulieL

The first 24 h: opioid administration in people with spinal cord injury and neurologic recovery.

第一个 24 小时：脊髓损伤和神经功能恢复患者服用阿片类药物。

• DOI: 10.1038/s41393-020-0483-x
• 发表时间: 2020
• 期刊: Spinal cord
• 影响因子: 2.2
• 作者: Stampas,Argyrios;Pedroza,Claudia;Bush,JenniferN;Ferguson,AdamR;Kramer,JohnLKipling;Hook,Michelle
• 通讯作者: Hook,Michelle

Utility of a brief assessment of opioid demand among post-discharge trauma care patients.

出院后创伤护理患者对阿片类药物需求的简要评估的效用。

• DOI: 10.1037/pha0000412
• 发表时间: 2020
• 期刊: Experimental and clinical psychopharmacology
• 影响因子: 2.3
• 作者: Yoon,JinH;Suchting,Robert;Kessler,Danielle;Soder,HeatherE;Kapoor,Shweta;Stotts,AngelaL;Heads,AngelaM;Harvin,JohnA;Green,CharlesE;Lane,ScottD;Schmitz,JoyM
• 通讯作者: Schmitz,JoyM